200,000+ products from a single source!
sales@angenechem.com
180468-39-7 | 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, hydrochloride (1:1), (1S)-
CAS No: 180468-39-7 Catalog No: AG002203 MDL No:MFCD09953430
Product Description
Catalog Number:
AG002203
Chemical Name:
2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, hydrochloride (1:1), (1S)-
CAS Number:
180468-39-7
Molecular Formula:
C23H27ClN2O2
Molecular Weight:
398.9257
MDL Number:
MFCD09953430
IUPAC Name:
[(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate;hydrochloride
InChI:
InChI=1S/C23H26N2O2.ClH/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19;/h1-9,18,21-22H,10-16H2;1H/t21-,22-;/m0./s1
InChI Key:
YAUBKMSXTZQZEB-VROPFNGYSA-N
SMILES:
O=C(N1CCc2c([C@@H]1c1ccccc1)cccc2)O[C@H]1CN2CCC1CC2.Cl
Properties
Complexity:
525
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2
Defined Atom Stereocenter Count:
2
Defined Bond Stereocenter Count:
0
Exact Mass:
398.176g/mol
Formal Charge:
0
Heavy Atom Count:
28
Hydrogen Bond Acceptor Count:
3
Hydrogen Bond Donor Count:
1
Isotope Atom Count:
0
Molecular Weight:
398.931g/mol
Monoisotopic Mass:
398.176g/mol
Rotatable Bond Count:
3
Topological Polar Surface Area:
32.8A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
| Title | Journal |
|---|---|
| Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. | Expert opinion on drug metabolism & toxicology 20121101 |
| Efficacy and safety of solifenacin to treat overactive bladder symptoms in patients with idiopathic normal pressure hydrocephalus: an open-label, multicenter, prospective study. | Neurourology and urodynamics 20120901 |
| Solifenacin for overactive bladder: a systematic review and meta-analysis. | International urogynecology journal 20120801 |
| Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review. | Annals of internal medicine 20120619 |
| Urinary urgency: a review of its assessment as the key symptom of the overactive bladder syndrome. | World journal of urology 20120601 |
| Solifenacin objectively decreases urinary sensation in women with overactive bladder syndrome. | International urology and nephrology 20120401 |
| Improvement of urinary dysfunction after kidney transplantation by administration of the antimuscarinic agent--prospective randomized controlled study. | Transplantation 20120327 |
| The efficacy and safety of solifenacin in patients with overactive bladder syndrome. | Collegium antropologicum 20120301 |
| Which anticholinergic drug for overactive bladder symptoms in adults. | The Cochrane database of systematic reviews 20120118 |
| Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. | Urologic nursing 20120101 |
| Adding to the evidence base: efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. | Urologic nursing 20120101 |
| Co-administration of an α(1) -blocker improves the efficacy and safety of antimuscarinic agents in rats with detrusor overactivity. | International journal of urology : official journal of the Japanese Urological Association 20111201 |
| Urothelial/lamina propria spontaneous activity and the role of M3 muscarinic receptors in mediating rate responses to stretch and carbachol. | Urology 20111201 |
| Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy. | Neurourology and urodynamics 20111101 |
| [Treatment for overactive bladder]. | Der Urologe. Ausg. A 20111001 |
| Solifenacin may improve sleep quality in patients with overactive bladder and sleep disturbance. | Urology 20110901 |
| A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. | British journal of clinical pharmacology 20110801 |
| The effect of solifenacin on urethral sphincter morphology. | International urogynecology journal 20110801 |
| Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome. | The journal of obstetrics and gynaecology research 20110801 |
| Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. | The Journal of urology 20110701 |
| Tadalafil versus solifenacin for persistent storage symptoms after prostate surgery in patients with erectile dysfunction: a prospective randomized study. | International journal of urology : official journal of the Japanese Urological Association 20110701 |
| Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms--ASSIST, randomized controlled study. | Urology 20110701 |
| Which single-item measures of overactive bladder symptom treatment correlate best with patient satisfaction? | Neurourology and urodynamics 20110401 |
| Evaluation of brain anticholinergic activities of urinary spasmolytic drugs using a high-throughput radio receptor bioassay. | Journal of the American Geriatrics Society 20110301 |
| Tolerability of solifenacin and oxybutynin immediate release in older (> 65 years) and younger (≤ 65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study. | Current medical research and opinion 20110201 |
| Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study. | International journal of clinical practice 20110201 |
| [Treatment with solifenacin reduces urinary urgency and improves quality of life. Results of the non-interventional CAP-study]. | MMW Fortschritte der Medizin 20110113 |
| Efficacy and tolerability of solifenacin in patients aged ≥ 65 years with overactive bladder: post-hoc analysis of 2 open-label studies. | Postgraduate medicine 20110101 |
| [Impact of overactive bladder on sexual function in women]. | Urologia 20110101 |
| Overactive bladder syndrome: what is the role of evidence of detrusor overactivity in the cystometric study? | Minerva urologica e nefrologica = The Italian journal of urology and nephrology 20101201 |
| Determination of solifenacin in human plasma by liquid chromatography-tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20101201 |
| A validated rapid stability-indicating method for the determination of related substances in solifenacin succinate by ultra-fast liquid chromatography. | Journal of chromatographic science 20101101 |
| Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. | Current medical research and opinion 20101001 |
| Loss of muscarinic and purinergic receptors in urinary bladder of rats with hydrochloric acid-induced cystitis. | Urology 20101001 |
| Prospective open label study of solifenacin for overactive bladder in children. | The Journal of urology 20101001 |
| Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms. | Journal of the Formosan Medical Association = Taiwan yi zhi 20101001 |
| Urodynamic effects of solifenacin in untreated female patients with symptomatic overactive bladder. | International journal of urology : official journal of the Japanese Urological Association 20100901 |
| The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. | BJU international 20100801 |
| Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. | International urogynecology journal 20100701 |
| New strategies for medical management of overactive bladder in children. | Current opinion in urology 20100701 |
| Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes. | The aging male : the official journal of the International Society for the Study of the Aging Male 20100601 |
| Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial. | The Journal of urology 20100501 |
| Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: results from a randomized study. | BJU international 20100401 |
| Solifenacin: scientific evidence in the treatment of overactive bladder. | Archivos espanoles de urologia 20100401 |
| Pediatrics: combining antimuscarinics shows promise for overactive bladder. | Nature reviews. Urology 20100201 |
| The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially urgency episodes. | Journal of pharmacological sciences 20100101 |
| Solifenacin pharmacology. | Archivos espanoles de urologia 20100101 |
| Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder. | Journal of medical economics 20100101 |
| [Solifenacin in treatment of the overactive bladder syndrome--diagnosis, clinical management and results]. | Akusherstvo i ginekologiia 20100101 |
| [Treatment of overactive urinary bladder with imperative urinary incontinence in women]. | Urologiia (Moscow, Russia : 1999) 20100101 |
| Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. | The Journal of urology 20091201 |
| Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. | International journal of clinical practice 20091201 |
| Impact of solifenacin on quality of life, medical care use, work productivity, and health utility in the elderly: an exploratory subgroup analysis. | The American journal of geriatric pharmacotherapy 20091201 |
| Anticholinergic drug use for overactive bladder in Sweden: a nationwide pharmacoepidemiological study. | International urogynecology journal and pelvic floor dysfunction 20091101 |
| Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. | Expert opinion on drug safety 20091101 |
| Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome. | BJU international 20091001 |
| Solifenacin for therapy resistant overactive bladder. | The Journal of urology 20091001 |
| Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. | Postgraduate medicine 20090901 |
| Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice. | European journal of pharmacology 20090801 |
| Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin. | International urogynecology journal and pelvic floor dysfunction 20090601 |
| Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. | The Journal of pharmacology and experimental therapeutics 20090301 |
| In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder. | British journal of pharmacology 20090301 |
| Solifenacin succinate for the treatment of overactive bladder. | Expert opinion on drug metabolism & toxicology 20090301 |
| Solifenacin in the treatment of overactive bladder syndrome in Italian patients: pharmacoeconomic evaluation. | Journal of medical economics 20090301 |
| Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. | BJU international 20090201 |
| Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity. | Neurourology and urodynamics 20090101 |
| The cost utility of solifenacin in the treatment of overactive bladder. | International urology and nephrology 20090101 |
| Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. | Urology 20090101 |
| Solifenacin for overactive bladder in women unsuccessfully treated with immediate release oxybutynin: a pilot study. | Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology 20090101 |
| Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study. | Clinical drug investigation 20090101 |
| Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries. | Acta obstetricia et gynecologica Scandinavica 20090101 |
| Clinical pharmacokinetics and pharmacodynamics of solifenacin. | Clinical pharmacokinetics 20090101 |
| Response to 'Suspected differential interactions of digoxin with imidafenacin and propantheline; some thoughts for introspection'. | Drug metabolism and pharmacokinetics 20090101 |
| Highly sensitive and rapid LC-ESI-MS/MS method for the simultaneous quantification of uroselective alpha1-blocker, alfuzosin and an antimuscarinic agent, solifenacin in human plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20081215 |
| QT prolongation and torsade de pointes associated with solifenacin in an 81-year-old woman. | British journal of clinical pharmacology 20081201 |
| [Efficacy and safety of solifenacin in daily clinical practice--clinical study phase IV]. | Ceska gynekologie 20081201 |
| Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. | BJU international 20081101 |
| Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study. | International journal of clinical practice 20081101 |
| Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. | Clinical therapeutics 20081001 |
| A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. | Current medical research and opinion 20080801 |
| [Urinary urgency]. | MMW Fortschritte der Medizin 20080731 |
| Solifenacin at 3 years: a review of efficacy and safety. | Postgraduate medicine 20080701 |
| Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER. | Current medical research and opinion 20080601 |
| [Overactive bladder. When it's pressing, immediate help is indicated]. | MMW Fortschritte der Medizin 20080515 |
| Photodistributed lichenoid drug eruption secondary to solifenacin. | Clinical and experimental dermatology 20080501 |
| Solifenacin-induced small bowel pseudo-obstruction. | Journal of hospital medicine 20080301 |
| Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial. | International journal of clinical practice 20080101 |
| Pharmacological effects of solifenacin on human isolated urinary bladder. | Pharmacology 20080101 |
| Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study. | Drug safety 20080101 |
| [Assessment of symptoms severity in patients with overactive bladder]. | Urologiia (Moscow, Russia : 1999) 20080101 |
| Effects of intravenously and orally administered solifenacin succinate (YM905) on carbachol-induced intravesical pressure elevation and salivary secretion in mice. | Biological & pharmaceutical bulletin 20071201 |
| Determination of solifenacin succinate, a novel muscarinic receptor antagonist, and its major metabolite in rat plasma by semi-micro high performance liquid chromatography. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20071115 |
| Comparative in vivo uroselectivity profiles of anticholinergics, tested in a novel anesthetized rabbit model. | European journal of pharmacology 20071031 |
| An unusual cause of postoperative detrusor overactivity. | International urogynecology journal and pelvic floor dysfunction 20071001 |
| Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. | European urology 20071001 |
| Comparison of the efficacy and tolerability of solifenacin succinate with or without previous use of trospium chloride. | International urogynecology journal and pelvic floor dysfunction 20070901 |
| Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. | BJU international 20070901 |
| Pharmacologic management of overactive bladder. | Clinical interventions in aging 20070901 |
| Number of daytime micturitions and volume voided per micturition in the evaluation of efficacy of drugs for overactive bladder: findings from randomized clinical trials. | European urology 20070801 |
| Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms. | International urogynecology journal and pelvic floor dysfunction 20070701 |
| Overactive bladder treatments in early phase clinical trials. | Expert opinion on investigational drugs 20070701 |
| Update on drugs for overactive bladder syndrome. | Drug and therapeutics bulletin 20070601 |
| [Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder]. | Der Urologe. Ausg. A 20070401 |
| Solifenacin treatment for overactive bladder in black patients: patient-reported symptom bother and health-related quality of life outcomes. | Current medical research and opinion 20070401 |
| Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes. | The Annals of pharmacotherapy 20070301 |
| Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. | Biological & pharmaceutical bulletin 20070101 |
| Redefining response in overactive bladder syndrome. | BJU international 20070101 |
| Pharmacokinetics, safety, and tolerability of solifenacin in patients with renal insufficiency. | Journal of pharmacological sciences 20070101 |
| [Solifenacin in the treatment of patients with hyperactive urinary bladder]. | Urologiia (Moscow, Russia : 1999) 20070101 |
| [A placebo-controlled, double-blind, randomized trial of single daily dose of anti-muscarinic drug solifenacin succinate in patients with overactive bladder]. | Akusherstvo i ginekologiia 20070101 |
| Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder. | Expert opinion on pharmacotherapy 20061201 |
| [Pharmacological and clinical profile of solifenacin succinate (Vesicare) developed as a new therapeutic agent for overactive bladder]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20061201 |
| Open-label study of the safety and pharmacokinetics of solifenacin in subjects with hepatic impairment. | Journal of pharmacological sciences 20061201 |
| Solifenacin succinate (VESIcare): overactive bladder therapy. | Urologic nursing 20061201 |
| New developments in the treatment of urinary incontinence. | Minerva urologica e nefrologica = The Italian journal of urology and nephrology 20061201 |
| Solifenacin. | The Urologic clinics of North America 20061101 |
| Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites? | Naunyn-Schmiedeberg's archives of pharmacology 20061101 |
| Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). | Clinical therapeutics 20061101 |
| Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin. | International urogynecology journal and pelvic floor dysfunction 20060901 |
| Solifenacin succinate for the treatment of symptoms of overactive bladder. | Clinical therapeutics 20060901 |
| Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: A pooled analysis. | The American journal of geriatric pharmacotherapy 20060901 |
| Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects. | British journal of clinical pharmacology 20060801 |
| Solifenacin significantly improves all symptoms of overactive bladder syndrome. | International journal of clinical practice 20060801 |
| Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. | Urology 20060801 |
| [Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder]. | Der Urologe. Ausg. A 20060701 |
| Comparative evaluation of exocrine muscarinic receptor binding characteristics and inhibition of salivation of solifenacin in mice. | Biological & pharmaceutical bulletin 20060701 |
| Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers. | Basic & clinical pharmacology & toxicology 20060701 |
| Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence. | International urogynecology journal and pelvic floor dysfunction 20060601 |
| Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence. | BJU international 20060601 |
| Using anticholinergics to treat overactive bladder: the issue of treatment tolerability. | The American journal of medicine 20060301 |
| The emergence of new drugs for overactive bladder. | Expert opinion on emerging drugs 20060301 |
| Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. | The American journal of geriatric pharmacotherapy 20060301 |
| New drugs 06, part I. | Nursing 20060201 |
| Re: Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70. | European urology 20060101 |
| Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis. | Current medical research and opinion 20060101 |
| Solifenacin in overactive bladder syndrome. | Drugs 20060101 |
| Solifenacin versus tolterodine--a head-to-head study: finally! But not final? | Current urology reports 20051101 |
| [Drug discovery in the fields of urology: tamsulosin and solifenacin]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20051101 |
| Synthesis and antimuscarinic properties of quinuclidin-3-yl 1,2,3,4-tetrahydroisoquinoline-2-carboxylate derivatives as novel muscarinic receptor antagonists. | Journal of medicinal chemistry 20051020 |
| Solifenacin in the management of the overactive bladder syndrome. | International journal of clinical practice 20051001 |
| A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. | European urology 20050901 |
| Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis. | European urology 20050901 |
| Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study. | Clinical therapeutics 20050901 |
| Solifenacin and darifenacin for overactive bladder. | Obstetrics and gynecology 20050801 |
| New treatment options for overactive bladder. | South Dakota journal of medicine 20050601 |
| Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice. | British journal of pharmacology 20050501 |
| Effect of age on the pharmacokinetics of solifenacin in men and women. | International journal of clinical pharmacology and therapeutics 20050501 |
| Effects of solifenacin succinate (YM905) on detrusor overactivity in conscious cerebral infarcted rats. | European journal of pharmacology 20050404 |
| Solifenacin and darifenacin for overactive bladder. | The Medical letter on drugs and therapeutics 20050314 |
| Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. | European urology 20050301 |
| Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. | BJU international 20050101 |
| New molecular entity: Vesicare, Yamanouchi/GlaxoSmithKline solifenacin. | Geriatrics 20050101 |
| New drugs: acamprosate calcium and solifenacin succinate. | Journal of the American Pharmacists Association : JAPhA 20050101 |
| Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg. | Current medical research and opinion 20050101 |
| [Neurological aspect of the hyperactive urinary bladder syndrome]. | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20050101 |
| Solifenacin in overactive bladder syndrome. | Drugs & aging 20050101 |
| Solifenacin in overactive bladder syndrome: a viewpoint by Scott Serels. | Drugs & aging 20050101 |
| Solifenacin in overactive bladder: a viewpoint by Hashim Hashim. | Drugs & aging 20050101 |
| Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. | The Journal of urology 20041101 |
| The emerging role of solifenacin in the treatment of overactive bladder. | Expert opinion on investigational drugs 20041001 |
| Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium, and duloxetine. | Current urology reports 20041001 |
| Elevating our therapeutic expectations in overactive bladder. | Journal of the American Academy of Nurse Practitioners 20041001 |
| Pharmacokinetics and safety of solifenacin succinate in healthy young men. | Journal of clinical pharmacology 20040901 |
| [Overactive bladder. New anticholinergic drug controls urinary urge]. | MMW Fortschritte der Medizin 20040708 |
| Food does not affect the pharmacokinetics of solifenacin, a new muscarinic receptor antagonist: results of a randomized crossover trial. | British journal of clinical pharmacology 20040701 |
| [In overactive bladder, above all urgency is stressful. The patients know the site of each toilet]. | MMW Fortschritte der Medizin 20040527 |
| In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. | European journal of pharmacology 20040525 |
| Solifenacin: treatment of overactive bladder. | Drugs of today (Barcelona, Spain : 1998) 20040401 |
| Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. | BJU international 20040201 |
| Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells. | Life sciences 20040102 |
| Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. | BJU international 20040101 |
| Solifenacin demonstrates high absolute bioavailability in healthy men. | Drugs in R&D 20040101 |
| [Urinary incontinence: new pharmacologic therapies]. | Revista de medicina de la Universidad de Navarra 20040101 |
| M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. | Naunyn-Schmiedeberg's archives of pharmacology 20020801 |
| Effects of YM905, a novel muscarinic M3-receptor antagonist, on experimental models of bowel dysfunction in vivo. | Japanese journal of pharmacology 20010701 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.